Abstract: A pharmaceutically acceptable transdermal composition for the treatment of patients with musculoskeletal connective tissue fibrosis or a disorder including Dupuytren's Contracture, Peyronie's disease, Ledderhose disease, or Knuckle Pads, includes an active composition and a base composition. The active composition is present in the transdermal composition in an amount of about 10% to about 40% by weight of the transdermal composition and includes one or more growth factor antagonists. The base composition is present in an amount of about 60% to about 90% by weight of the transdermal composition and comprises a transdermal delivery system or transdermal carrier. A method of treating patients with musculoskeletal connective tissue fibrosis, including topically applying the transdermal composition in effective amount to the affected tissue is further disclosed.

Abstract: Embodiments of the present disclosure are directed to methods of treating, reducing or preventing fibrosis or scarring including administering a therapeutic molecular agent selected from the group consisting of an agent that inhibits chaperonin containing T-complex polypeptide subunit eta polypeptide (“CCT-eta”), an agent that inhibits ?-Smooth Muscle Actin (“?-SMA”), or a combination thereof. In embodiments, the fibrosis may include Dupuytren's contracture, Peyronie's disease, pulmonary fibrosis, cirrhosis, interstitial lung disease or scarring alopecia.

Abstract: Embodiments of the present disclosure are directed to methods of treating, reducing or preventing fibrosis or scarring including administering a therapeutic molecular agent selected from the group consisting of an agent that inhibits chaperonin containing T-complex polypeptide subunit eta polypeptide (“CCT-eta”), an agent that inhibits ?-Smooth Muscle Actin (“?-SMA”), or a combination thereof. In embodiments, the fibrosis may include Dupuytren's contracture, Peyronie's disease, pulmonary fibrosis, cirrhosis, interstitial lung disease or scarring alopecia.

Abstract: Methods of treating, reducing or preventing fibrosis or scarring including administering a therapeutic molecular agent selected from the group consisting of an agent that inhibits chaperonin containing Tcomplex polypeptide subunit eta polypeptide (“CCT-eta”), an agent that inhibits a-Smooth Muscle Actin (“a-SMA”), or a combination thereof, are presented. The fibrosis may include Dupuytren's contracture, Peyronie's disease, pulmonary fibrosis, cirrhosis, interstitial lung disease or scarring alopecia.